Please login to the form below

Not currently logged in


This page shows the latest Skysona news and features for those working in and with pharma, biotech and healthcare.

bluebird bio’s sickle cell gene therapy accepted for FDA priority review

bluebird bio’s sickle cell gene therapy accepted for FDA priority review

disorder. In September last year, the company’s Skysona (elivaldogene autotemcel) gene therapy was granted FDA accelerated approval to slow the progression of neurologic dysfunction in certain patients with cerebral adrenoleukodystrophy,

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts


Add my company
Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys...

Latest intelligence

Actinic keratosis – a common skin condition that can lead to skin cancer
PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...